Tags

Type your tag names separated by a space and hit enter

Glast-expressing progenitor cells contribute to heterotopic ossification.
Bone. 2013 Mar; 53(1):194-203.BONE

Abstract

Heterotopic ossification (HO), acquired or hereditary, is the formation of true bone outside the normal skeleton. Although the lineages of cells contributing to bone formation during normal development are well defined, the precise lineages of cells that contribute to HO are not clear. This study utilized Cre-lox based genetic lineage tracing to examine the contribution to HO of cells that expressed either FoxD1 or Glast. Both lineages contributed broadly to different normal tissues, and FoxD1-cre labeled cells contributed to normal bone formation. Despite the similarity in labeling patterns of normal tissues, and the significant contribution of FoxD1-cre labeled cells to normal bone, only Glast-creERT labeled progenitors contributed significantly to HO at all stages, suggesting that the cell populations that normally contribute to physiological bone formation, such as the Foxd1-cre labeled cells, may not participate in pathological HO. Further, identification of Glast-expressing cells as precursors that give rise to HO should help with the molecular targeting of this population both for the prevention and for the treatment of HO.

Authors+Show Affiliations

Department of Neurology, Northwestern University Feinberg Medical School, 303 East Chicago Avenue, Chicago, IL 60611, USA. l-kan@northwestern.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23262027

Citation

Kan, Lixin, et al. "Glast-expressing Progenitor Cells Contribute to Heterotopic Ossification." Bone, vol. 53, no. 1, 2013, pp. 194-203.
Kan L, Peng CY, McGuire TL, et al. Glast-expressing progenitor cells contribute to heterotopic ossification. Bone. 2013;53(1):194-203.
Kan, L., Peng, C. Y., McGuire, T. L., & Kessler, J. A. (2013). Glast-expressing progenitor cells contribute to heterotopic ossification. Bone, 53(1), 194-203. https://doi.org/10.1016/j.bone.2012.12.008
Kan L, et al. Glast-expressing Progenitor Cells Contribute to Heterotopic Ossification. Bone. 2013;53(1):194-203. PubMed PMID: 23262027.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glast-expressing progenitor cells contribute to heterotopic ossification. AU - Kan,Lixin, AU - Peng,Chian-Yu, AU - McGuire,Tammy L, AU - Kessler,John A, Y1 - 2012/12/20/ PY - 2012/10/10/received PY - 2012/11/28/revised PY - 2012/12/09/accepted PY - 2012/12/25/entrez PY - 2012/12/25/pubmed PY - 2013/8/21/medline SP - 194 EP - 203 JF - Bone JO - Bone VL - 53 IS - 1 N2 - Heterotopic ossification (HO), acquired or hereditary, is the formation of true bone outside the normal skeleton. Although the lineages of cells contributing to bone formation during normal development are well defined, the precise lineages of cells that contribute to HO are not clear. This study utilized Cre-lox based genetic lineage tracing to examine the contribution to HO of cells that expressed either FoxD1 or Glast. Both lineages contributed broadly to different normal tissues, and FoxD1-cre labeled cells contributed to normal bone formation. Despite the similarity in labeling patterns of normal tissues, and the significant contribution of FoxD1-cre labeled cells to normal bone, only Glast-creERT labeled progenitors contributed significantly to HO at all stages, suggesting that the cell populations that normally contribute to physiological bone formation, such as the Foxd1-cre labeled cells, may not participate in pathological HO. Further, identification of Glast-expressing cells as precursors that give rise to HO should help with the molecular targeting of this population both for the prevention and for the treatment of HO. SN - 1873-2763 UR - https://www.unboundmedicine.com/medline/citation/23262027/Glast_expressing_progenitor_cells_contribute_to_heterotopic_ossification_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S8756-3282(12)01425-1 DB - PRIME DP - Unbound Medicine ER -